Cited 53 times in
Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경식 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 최기홍 | - |
dc.contributor.author | 최진섭 | - |
dc.contributor.author | 한광협 | - |
dc.contributor.author | 한대훈 | - |
dc.contributor.author | 정재욱 | - |
dc.date.accessioned | 2019-12-18T00:21:31Z | - |
dc.date.available | 2019-12-18T00:21:31Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1068-9265 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/173013 | - |
dc.description.abstract | BACKGROUND: Locally advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) has a poor oncological outcome. This study evaluated the oncological outcomes and prognostic factors of surgical resection after downstaging with localized concurrent chemoradiotherapy (CCRT) followed by hepatic arterial infusion chemotherapy (HAIC). METHODS: From 2005 to 2014, 354 patients with locally advanced HCC underwent CCRT followed by HAIC. Among these patients, 149 patients with PVTT were analyzed. Exclusion criteria included a total bilirubin ≥ 2 mg/dL, platelet count < 100,000/μL, and indocyanine green retention test (ICG R15) > 20%. During the same study period, 18 patients with PVTT underwent surgical resection as the first treatment. Clinicopathological characteristics and oncological outcomes between groups were compared. RESULTS: Among 98 patients in the CCRT group, 26 patients (26.5%) underwent subsequent curative resection. The median follow-up period was 13 months (range 1-131 months). Disease-specific survival differed significantly between the resection after localized CCRT group and the resection-first group {median 62 months (95% confidence interval [CI] 22.99-101.01) versus 15 months (95% CI 10.84-19.16), respectively; P = 0.006}. Multivariate analyses showed that achievement of radiologic response was an independently good prognostic factor for both disease-specific survival (P = 0.039) and disease-free survival (P = 0.001) CONCLUSIONS: Localized CCRT could be an effective tool for identifying optimal candidates for surgical treatment with favorable tumor biology. Furthermore, with a 26.5% resection rate and 100% response in PVTT for resection after CCRT, our localized CCRT protocol may be ideal for PVTT. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | ANNALS OF SURGICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Carcinoma, Hepatocellular/mortality | - |
dc.subject.MESH | Carcinoma, Hepatocellular/pathology | - |
dc.subject.MESH | Carcinoma, Hepatocellular/therapy* | - |
dc.subject.MESH | Chemoradiotherapy/mortality* | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Hepatectomy/mortality* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infusions, Intra-Arterial | - |
dc.subject.MESH | Liver Neoplasms/mortality | - |
dc.subject.MESH | Liver Neoplasms/pathology | - |
dc.subject.MESH | Liver Neoplasms/therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local/mortality | - |
dc.subject.MESH | Neoplasm Recurrence, Local/pathology | - |
dc.subject.MESH | Neoplasm Recurrence, Local/therapy* | - |
dc.subject.MESH | Portal Vein/pathology* | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Venous Thrombosis/mortality | - |
dc.subject.MESH | Venous Thrombosis/pathology | - |
dc.subject.MESH | Venous Thrombosis/therapy* | - |
dc.title | Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Jae Uk Chong | - |
dc.contributor.googleauthor | Gi Hong Choi | - |
dc.contributor.googleauthor | Dai Hoon Han | - |
dc.contributor.googleauthor | Kyung Sik Kim | - |
dc.contributor.googleauthor | Jinsil Seong | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Jin Sub Choi | - |
dc.identifier.doi | 10.1245/s10434-018-6653-9 | - |
dc.contributor.localId | A00299 | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A04046 | - |
dc.contributor.localId | A04199 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A04273 | - |
dc.relation.journalcode | J00179 | - |
dc.identifier.eissn | 1534-4681 | - |
dc.identifier.pmid | 30083834 | - |
dc.identifier.url | https://link.springer.com/article/10.1245%2Fs10434-018-6653-9 | - |
dc.contributor.alternativeName | Kim, Kyung Sik | - |
dc.contributor.affiliatedAuthor | 김경식 | - |
dc.contributor.affiliatedAuthor | 성진실 | - |
dc.contributor.affiliatedAuthor | 최기홍 | - |
dc.contributor.affiliatedAuthor | 최진섭 | - |
dc.contributor.affiliatedAuthor | 한광협 | - |
dc.contributor.affiliatedAuthor | 한대훈 | - |
dc.citation.volume | 25 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 3308 | - |
dc.citation.endPage | 3315 | - |
dc.identifier.bibliographicCitation | ANNALS OF SURGICAL ONCOLOGY, Vol.25(11) : 3308-3315, 2018 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.